Despite considerable advances in the treatment of multiple myeloma (MM) in the last
decade, a substantial proportion of patients do not respond to current therapies or have a …

New approaches to stratify multiple myeloma patients based on prognosis and therapeutic
decision-making, or prediction, are needed since patients are currently managed in a similar …

Background Bortezomib, lenalidomide, and dexamethasone (VRd) is a preferred first-line
treatment option for patients with newly diagnosed multiple myeloma. Whether the addition …

CD38-targeting immunotherapy is approved in combination with lenalidomide and
dexamethasone in patients with newly diagnosed multiple myeloma (NDMM) that are …

The prognostic value of minimal residual disease (MRD) for progression-free survival (PFS)
and overall survival (OS) was evaluated in a large cohort of patients with multiple myeloma …

Background Anti-CD38 monoclonal antibodies have consistently shown increased efficacy
when added to standard of care for patients with multiple myeloma. We aimed to assess the …

Since the publication of the article entitled “Multiple Myeloma: EHA-ESMO Clinical Practice
Guidelines for Diagnosis, Treatment and Follow-up”(HemaSphere. 2021; 5: e528) …

Background Bortezomib, lenalidomide, and dexamethasone (VRd) is a standard therapy for
newly diagnosed multiple myeloma. Carfilzomib, a next-generation proteasome inhibitor, in …

Multiple myeloma (MM) accounts for 1% of all cancers and∼ 10% of all haematological
malignancies. The incidence in Europe is 4.5–6.0/100 000/year with a median age at …

The introduction of novel agents has led to major improvements in clinical outcomes for
patients with multiple myeloma. To shorten evaluation times for new treatments, health …